Gio Fidelito

Dual inhibition of ACLY and ACSS2 by EVT0185 reduces steatosis, hepatic stellate cell activation, and fibrosis in mouse models of MASH Di Pastena et al. report that EVT0185, a dual ACLY/ACSS2 inhibitor, improves insulin sensitivity and steatosis while reducing fibrosis in MASH. By inhibiting acetate-driven cholesterol biosynthesis, w...

Excited to have contributed to this work!
In Matt Watt's lab at UniMelb, we tested the efficacy of this compounds using the human precision-cut liver slices in collaboration with surgeons at Austin Hospital.

www.cell.com/cell-metabol...

If you are interested in cancer metabolism, CRISPR screening, lipid metabolism, and mevalonate-cholesterol metabolism, please have a read!

Lipid-metabolism-focused CRISPR screens identify enzymes of the mevalonate pathway as essential for prostate cancer growth Fidelito et al. conducted lipid-metabolism-focused CRISPR screens and identified the dependency of prostate cancer on enzymes involved in the mevalonate pathway. Further validation identified NUS1 as ...

Excited to share that the final research chapter of my thesis is now published!
Our study explored which aspects of lipid metabolism are required for prostate cancer. The findings offer intriguing insights and many unanswered questions.

Frontiers | Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality? Prostate cancer invokes major shifts in gene transcription and metabolic signaling to mediate alterations in nutrient acquisition and metabolic substrate sel...

If you're interested in prostate cancer metabolism, please read the review article we wrote several years ago. I believe it's a good introduction for newcomers.

Lipidome profiling in advanced metabolic liver disease identifies phosphatidylserine synthase 1 as a regulator of hepatic lipoprotein metabolism Anari et al. show that hepatic accumulation of phosphatidylserine (PS) is associated with hypertriglyceridemia in metabolic dysfunction-associated steatohepatitis (MASH). Increasing expression of PS synthase 1 (PSS1), an enzyme responsible for PS generation, remodels liver-derived lipoprotein composition, which inhibits lipid deposition in skeletal muscle, leading to systemic hypertriglyceridemia.

Excited to see this collaborative work published! We identify how changes in hepatic lipid metabolism can alter peripheral metabolism. www.cell.com/cell-reports...

I forgot to mention my baby project on prostate cancer lineage plasticity and metabolism.

Multi-substrate Metabolic Tracing Reveals Marked Heterogeneity and Dependency on Fatty Acid Metabolism in Human Prostate Cancer AbstractCancer cells undergo metabolic reprogramming to meet increased bioenergetic demands. Studies in cells and mice have highlighted the importance of oxidative metabolism and lipogenesis in prosta...

And here I am shamelessly plugging the first publication of my PhD. More to come hopefully soon 🤞
aacrjournals.org/mcr/article/...

And of course, as I am based in Matt Watt's lab focusing on liver metabolism, I am also interested in fatty liver and HCC. Looking forward to connecting with anyone here.

It took me a while to eventually decide to stay in Melbourne to continue and expand some of my work and try to build my expertise. I am interested in all things metabolism, prostate cancer basic and translational research, and more recently intracellular fatty acid metabolism/trafficking.

I thought I'd like to introduce myself here. I recently completed my PhD from the University of Melbourne, where I delved into the complexity of prostate cancer metabolism. My research involved ex vivo metabolic tracing in PDX and lipid metabolism-focused CRISPR screen.